At enrollment, in the ILPSg, 17 women (16 with GDM and one with type 2 diabetes) needed only a basal insulin (χ2 0.002) and 36 had already been treated by short-acting insulin analogues, with no difference between ILPS and NPH groups (Table 1). The gene discussed is INS; the disease is type 2 diabetes mellitus.